Hemolytic Disease of the Fetus and Newborn (HDFN)
🔬 Understanding HDFN and Ensuring Positive Pregnancy Outcomes 🔬
Hemolytic Disease of the Fetus and Newborn (HDFN) continues to pose challenges for immunohematology laboratories. Identifying pregnant women at risk of developing anti-D and providing proper prophylaxis with anti-D immunoglobulin are crucial steps to prevent HDFN and reduce alloimmunization rates.
Once alloimmunization of anti-D is detected in a pregnant woman, it becomes essential to verify anti-D levels through antibody titration and monitor for fetal anemia. These steps play a vital role in ensuring positive pregnancy outcomes.
However, HDFN can also be caused by other antibody specificities besides anti-D. To achieve favorable outcomes in such cases, additional measures must be taken. Additionally, caring for mothers presenting with partial RhD requires specialized attention.
Join us in an informative webinar with Carla Dinardo, MD, PhD, the director of Fundação Pró-Sangue Hemocentro de São Paulo and a leading expert in Immunohematology. Dr. Dinardo will provide an overview of the physiopathology of this complex disease and shed light on how HDFN can be prevented, diagnosed, and effectively treated.
About Carla Dinardo: Carla Dinardo graduated in medicine in 2005 and further specialized in internal medicine and hematology and hemotherapy. As the head of the Immunohematology Division at Fundação Pró-Sangue Hemocentro de São Paulo, she has been actively involved in numerous projects concerning blood group system genetics, red blood cell alloimmunization, and general transfusion practice. Dr. Dinardo has made significant contributions as a researcher for the National Heart, Lung, and Blood Institute’s Recipient Epidemiology and Donor Evaluation Study III in Brazil, collaborating with the Vitalant Research Institute in San Francisco. Her dedication to the field has earned her the position of director of External Relations at Fundação Pró-Sangue and membership in the Young Professional Council of the International Society of Blood Transfusion, representing Latin America.
Don’t miss this opportunity to gain valuable insights into HDFN management and its impact on maternal and fetal health. Join us in our webinar with Dr. Carla Dinardo to broaden your understanding of this critical aspect of transfusion medicine. Register now! 📅📚👩⚕️
Sign up for immediate access to on‑demand webinar:
https://info.bio-rad.com/ww-IHD-transfusion-w13-registration-lp.html